SERES

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million

Retrieved on: 
星期四, 十一月 2, 2023
Biotechnology, General Health, Other Health, Health, Genetics, Gastroenterology, FDA, Research, Sale, Clostridioides, Clostridioides difficile infection, David Berry (inventor), CDI, Therapy, Nestlé, Workforce, Infection, Oak Tree, Growth, Oaktree Capital Management, Disease, Medicine, Risk, Recurrence, Term loan, Investment, Patient, Variometer, Pharmaceutical industry, Antibiotics, Nursing, Collaboration

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million.
  • Seres anticipates incurring a one-time charge of $5.0-$5.5 million in the fourth quarter of 2023, primarily related to the workforce reduction.
  • Seres reported a net loss of $47.9 million for the third quarter of 2023, as compared with a net loss of $60.0 million for the same period in 2022.
  • Net sales of VOWST for the third quarter of 2023, the first full quarter following launch, were $7.6 million based on 506 units.

Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST

Retrieved on: 
星期一, 十月 30, 2023
Biotechnology, Other Health, Health, Genetics, Clinical Trials, Therapy, David Berry (inventor), Broadcasting

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023.
  • Management will host a conference call with investors to discuss the results and corporate updates at 8:00 a.m.
  • To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com .
  • A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

SunCar Technology Group Inc. Releases Version 7.9.0 of its Insurance System

Retrieved on: 
星期四, 十一月 2, 2023
BYD, Geely Auto, Insurance, Minor planet, Nio, NEV, Online shopping

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- SunCar Technology Group Inc. ("SunCar", "we", or the "Company") (Nasdaq: SDA), a leading provider of digitalized enterprise automotive after-sales services and online auto insurance intermediation services in China, announced the release of its latest version of its cutting-edge digital insurance system, Version 7.9.0. This significant update reflects the Company's commitment to staying at the forefront of the evolving auto insurance industry. Version 7.9.0 is currently being deployed by 18 leading new energy vehicle (NEV) companies, including Geely Auto, BYD, Nio, Xiaopeng, Nio, Li Auto, and Seres.

Key Points: 
  • NEW YORK, Nov. 2, 2023 /PRNewswire/ -- SunCar Technology Group Inc. ("SunCar", "we", or the "Company") (Nasdaq: SDA), a leading provider of digitalized enterprise automotive after-sales services and online auto insurance intermediation services in China, announced the release of its latest version of its cutting-edge digital insurance system, Version 7.9.0.
  • This significant update reflects the Company's commitment to staying at the forefront of the evolving auto insurance industry.
  • Our system can now classify insurance image data by leveraging advanced image recognition technology, facilitating automatic storage and intelligent matching in real-world application scenarios.
  • Mr. YE Zaichang, Chairman and CEO of SunCar, commented, "I am proud of our team's relentless efforts in bringing forth the 7.9.0 version of our insurance system.

 Seres Therapeutics to Highlight VOWST™ Data at IDWeek

Retrieved on: 
星期四, 十月 12, 2023
Biotechnology, General Health, Pharmaceutical, Health, Food, Abstract, Medical diagnosis, CDI, Risk, Clostridioides difficile infection, US Foods, FDA, Therapy, Doctor of Philosophy, Variometer, Post hoc, Recurrence, Infection, David Berry (inventor), Patient, Pharmaceutical industry, Communications satellite

“The data we are presenting this year at IDWeek build upon our earlier findings that the gastrointestinal microbiome is similarly disrupted in patients with first or multiple rCDI.

Key Points: 
  • “The data we are presenting this year at IDWeek build upon our earlier findings that the gastrointestinal microbiome is similarly disrupted in patients with first or multiple rCDI.
  • The introduction of VOWST has provided a means to alleviate suffering and health risks associated with recurrent instances of this serious disease," said Matthew Henn, Ph.D., Chief Scientific Officer at Seres.
  • Report any infection that is suspected to have been transmitted by VOWST to Aimmune Therapeutics, Inc. at 1-833-246-2566.
  • To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics at 1-833-AIM-2KNO (1-833-246-2566), or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch .

Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
星期四, 九月 7, 2023
Biotechnology, General Health, Pharmaceutical, Health, Morgan, David Berry (inventor), Therapy, Conference, Pharmaceutical industry, Phonograph record, Private investigator

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 12:15 p.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 12:15 p.m.
  • ET.
  • An audio webcast of the presentation will be available under the “Investors and News” section of Seres’ website.
  • A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Retrieved on: 
星期二, 八月 1, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Stem Cells, Other Health, Biotechnology, Pharmaceutical, Health, Science, Canaccord Genuity, David Berry (inventor), Therapy, Conference, Pharmaceutical industry, Phonograph record, Cryptocurrency

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 3:00 p.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 3:00 p.m.
  • ET.
  • An audio webcast of the presentation will be available under the “Investors and News” section of Seres’ website.
  • A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023

Retrieved on: 
星期二, 八月 1, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, David Berry (inventor), Therapy, ID, Video game

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 8, 2023 at 8:30 a.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 8, 2023 at 8:30 a.m.
  • ET to discuss second quarter results and provide a general business update.
  • To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4844622.
  • To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com .

Seres Therapeutics Named to TIME100 Most Influential Companies List

Retrieved on: 
星期三, 六月 21, 2023
Biotechnology, General Health, Pharmaceutical, Health, Clostridioides difficile infection, CDI, Therapy, David Berry (inventor), Infection, Centers for Disease Control and Prevention, CDC, Patient, Variometer, FDA, TIME, Regulation of tobacco by the U.S. Food and Drug Administration, Death, Food, Pharmaceutical industry

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, has been named to the “TIME100 Most Influential Companies,” a list of 100 companies making an extraordinary impact around the world.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, has been named to the “TIME100 Most Influential Companies,” a list of 100 companies making an extraordinary impact around the world.
  • To develop the list, TIME solicited company nominations from multiple sectors from its editors and correspondents, as well as from industry experts.
  • Since being founded over a decade ago, Seres has led the development of microbiome therapeutics as a novel medical modality.
  • Seres is also advancing a pipeline of microbiome therapeutics for the prevention of infectious diseases, and for other serious diseases.

Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Retrieved on: 
星期六, 六月 17, 2023
Biotechnology, General Health, Pharmaceutical, Health, Infection, Clostridioides difficile infection, Science, CDI, Food and Drug Administration, ASM, David Berry (inventor), National University of Computer and Emerging Sciences, Multimedia, Hospital-acquired infection, CDC, Patient, Risk, Variometer, Growth, Recurrence, FDA, Therapy, Society, Spore, Food, Pharmaceutical industry, Vaccine

The analysis was featured as a late-breaker Emerging Science presentation at American Society of Microbiology (ASM) Microbe 2023 being held in Houston, TX (June 15-19).

Key Points: 
  • The analysis was featured as a late-breaker Emerging Science presentation at American Society of Microbiology (ASM) Microbe 2023 being held in Houston, TX (June 15-19).
  • Results showed that at baseline (pre-treatment), individuals experiencing a first recurrence or multiple recurrences exhibited a similarly low degree of gut microbiome diversity.
  • Report any infection that is suspected to have been transmitted by VOWST to Aimmune Therapeutics, Inc. at 1-833-246-2566.
  • To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics at 1-833-AIM-2KNO (1-833-246-2566), or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch .

NaaS Technology Inc. Reports Unaudited 2023 First Quarter Financial Results

Retrieved on: 
星期五, 六月 16, 2023
XPeng, DER, Marketing, NAAS, Original equipment manufacturer, Electricity, EPC, H.10, EVS, American depositary receipt, The Company, Acquisition, DST, Federal Reserve Board of Governors, EV, Generator, USD, Maqbool Dada, Growth, Brau Holding International, Geely Auto, US, Rise (education program), Kilowatt-hour, Research, RMB, Bank statement, ADS, Internet of things, Distributed generation, Network as a service, Phase 10, Translation, City, Ecosystem, AI, Cryptocurrency, Video game, Insurance, Renewable energy, Internet service provider, Huawei, Zeekr

BEIJING, June 16, 2023 /PRNewswire/ -- NaaS Technology Inc. ("NaaS" or the "Company") (Nasdaq: NAAS), the first U.S. listed EV charging service company in China, today announced its unaudited financial results for the first quarter ended March 31, 2023.

Key Points: 
  • BEIJING, June 16, 2023 /PRNewswire/ -- NaaS Technology Inc. ("NaaS" or the "Company") (Nasdaq: NAAS), the first U.S. listed EV charging service company in China, today announced its unaudited financial results for the first quarter ended March 31, 2023.
  • First Quarter 2023 Operational Highlights:
    Charging volume transacted through NaaS' network reached 1,023 GWh in the first quarter of 2023, representing an increase of 112% year over year.
  • First Quarter 2023 Financial Highlights:
    Revenues grew by 150% year over year and reached RMB36.2 million (US$5.3 million) in the first quarter of 2023.
  • First Quarter 2023 Financial Results:
    Total revenues reached RMB36.2 million (US$5.3 million) in the first quarter of 2023, representing an increase of 150% year over year.